Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. PRCD-associated retinitis pigmentosa in dogs and humans.Experimental eye research · 2026
   Article
2. Two genes, one culprit - a functional candidate validation of a SPATA7 deletion in dogs with day blindness/retinal degeneration.PLoS genetics · 2025
   Article
3. Novel photoreceptor-specific promoters for gene therapy in mid- to late-stage retinal degeneration.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
   Article
4. Recent advances in the understanding of cilia mechanisms and their applications as therapeutic targets.Frontiers in molecular biosciences · 2023
   Review

Corrections and comments

• Erratum for
  Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis.2021

Authors and funding

12 authors.

Funding

Abstract

PubMed holds no abstract for this paper.